

해외 바이오의약품 임상 현황 (2021.2.22~2021.2.28)

한국바이오의약품협회, 2021.3.2.  
출처: ClinicalTrials.gov

○ 미국 18건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	URL
NCT04750252	Safety and Tolerability of StroMel™ in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint	Osteo Arthritis Knee	Biological: StroMel	Akan Biosciences, LLC	Phase 1  Phase 2	
NCT04633252	Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer	Cancer Of Prostate Prostate Neoplasms	Drug: ADT Drug: Prednisone Drug: M7824 Drug: Docetaxel Drug: M9241	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 1  Phase 2	
NCT04199728	Use of a GLP-1R Agonist to Treat Opioid Use Disorder	Opiate Substitution Treatment Opioid-Related Disorders	Drug: Liraglutide Pen Injector Drug: Placebo	Milton S. Hershey Medical Center National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA)	Phase 1  Phase 2	
NCT04758702	The Clinical Impact of L-PRF, H-PRF or the Use of Surgical Stent on Palatal Donor Site Healing.	Lack of Keratinized Gingiva	Biological: L-PRF (Leucocyte- platelet rich fibrin) Biological: H-PRF (Horizontal -platelet rich fibrin) Device: Surgical stent	Abdo Y Ismail University of Kentucky	Phase 1	
NCT04714983	DNX-2440 for Resectable Colorectal Liver Metastasis	Liver Metastases Liver Metastasis Colon Cancer Colorectal Cancer Breast Cancer Gastric Cancer Periapillary Cancer Melanoma Renal Cell Cancer Sarcoma Squamous Cell Carcinoma Gastrointestinal Stromal Tumors	Biological: DNX-2440	DNatrix, Inc. H. Lee Moffitt Cancer Center and Research Institute	Phase 1	
NCT04560972	LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer	Extensive Stage Lung Small Cell Carcinoma	Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Protein Phosphatase 2A Inhibitor LB-100	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	
NCT04536077	Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients	Pancreatic Cancer Cancer of the Pancreas Pancreas Cancer	Drug: CDX-301 Drug: CDX-1140 Procedure: Research blood draw	Washington University School of Medicine CellDex Therapeutics The Foundation for Barnes-Jewish Hospital	Phase 2	
NCT04498325	Evaluating the Effect of NT-17, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)	COVID-19 SARS-CoV-2	Drug: NT-17 Drug: Placebo Procedure: Blood for research purposes Procedure: Blood for pharmacokinetic samples Procedure: Nasopharyngeal, oropharyngeal, or saliva swab Procedure: Blood for anti-drug antibody (ADA)	Washington University School of Medicine Neolmmune Tech	Phase 1	
NCT04462328	Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma	Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma	Drug: Durvalumab Drug: Acalabrutinib	Washington University School of Medicine AstraZeneca	Phase 1	
NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2	
NCT04761627	A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis	Psoriasis	Drug: Ustekinumab Drug: ABP 654	Amgen	Phase 3	
NCT04765384	A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)	Healthy	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 2	
NCT04677504	A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer	Biliary Tract Cancer	Drug: Atezolizumab Drug: Bevacizumab Other: Placebo Drug: Cisplatin Drug: Gemcitabine	Hoffmann-La Roche	Phase 2	
NCT04704843	A Study of JNJ-64304500 or Guselkumab in Adult Participants With Celiac Disease	Celiac Disease	Drug: JNJ-64304500 Drug: Guselkumab Drug: JNJ-64304500-Placebo Drug: Guselkumab-Placebo	Janssen Research & Development, LLC	Phase 1	
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2	
NCT04740918	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)	Metastatic Breast Cancer	Drug: Trastuzumab Emtansine Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinituzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	

○ 영국 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	URL
NCT04673630	Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma	Asthma	Biological: Tezepelumab	AstraZeneca Amgen	Phase 1	
NCT04740918	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)	Metastatic Breast Cancer	Drug: Trastuzumab Emtansine Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	
NCT04552899	A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: PRM-151 Drug: Placebo	Hoffmann-La Roche	Phase 3	
NCT04765384	A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)	Healthy	Biological: Ad26.COV2.S Other: Placebo	Janssen Vaccines & Prevention B.V.	Phase 2	
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinituzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	
NCT04677504	A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer	Biliary Tract Cancer	Drug: Atezolizumab Drug: Bevacizumab Other: Placebo Drug: Cisplatin Drug: Gemcitabine	Hoffmann-La Roche	Phase 2	
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2	
NCT04527380	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis	Juvenile Psoriatic Arthritis Enthesitis Related Arthritis	Drug: Ixekizumab Drug: Adalimumab	Eli Lilly and Company	Phase 3	

해외 바이오의약품 임상 현황 (2021.2.22~2021.2.28)

한국바이오의약품협회, 2021.3.2.  
출처: ClinicalTrials.gov

○ 프랑스 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	종류 URL
NCT04739202	Personalized Targeted IMMUNotherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)	Gastric Adenocarcinoma Metastatic Gastric Cancer Metastatic Adenocarcinoma Advanced Gastric Carcinoma	Drug: Atezolizumab + Ipatasertib Drug: Atezolizumab + Bevacizumab	Hospices Civils de Lyon	Phase 2	---
NCT04740918	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)	Metastatic Breast Cancer	Drug: Trastuzumab Emtansine Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04515394	Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) Amplification	Colorectal Neoplasms	Drug: Tepotinib Biological: Cetuximab	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2	---
NCT04527380	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis	Juvenile Psoriatic Arthritis Enthesitis Related Arthritis	Drug: Ixekizumab Drug: Adalimumab	Eli Lilly and Company	Phase 3	---
NCT04677504	A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer	Biliary Tract Cancer	Drug: Atezolizumab Drug: Bevacizumab Other: Placebo Drug: Cisplatin Drug: Gemcitabine	Hoffmann-La Roche	Phase 2	---
NCT04704843	A Study of JNJ-64304500 or Guselkumab in Adult Participants With Celiac Disease	Celiac Disease	Drug: JNJ-64304500 Drug: Guselkumab Drug: JNJ-64304500-Placebo Drug: Guselkumab-Placebo	Janssen Research & Development, LLC	Phase 1	---

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	종류 URL
NCT04740918	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)	Metastatic Breast Cancer	Drug: Trastuzumab Emtansine Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04527380	A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis	Juvenile Psoriatic Arthritis Enthesitis Related Arthritis	Drug: Ixekizumab Drug: Adalimumab	Eli Lilly and Company	Phase 3	---
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	---

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	종류 URL
NCT04712110	A Study of TAK-019 in Healthy Japanese Adults (COVID-19)	Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)	Biological: TAK-019 Biological: Placebo	Takeda	Phase 1  Phase 2	---

○ 일본 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	종류 URL
NCT04769908	Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis	ICC	Drug: Systemic Chemotherapy Drug: Lenvatinib Drug: Sintilimab	Sun Yat-sen University	Phase 2	---
NCT04660799	A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)	Lymphoma, Large B-Cell, Diffuse	Drug: Rituximab IV Drug: Rituximab SC Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Drug: Paracetamol Drug: Diphenhydramine hydrochloride or alternative antihistamine	Hoffmann-La Roche	Phase 2	---
NCT04740918	A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)	Metastatic Breast Cancer	Drug: Trastuzumab Emtansine Drug: Atezolizumab Other: Placebo	Hoffmann-La Roche	Phase 3	---
NCT04677504	A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer	Biliary Tract Cancer	Drug: Atezolizumab Drug: Bevacizumab Other: Placebo Drug: Cisplatin Drug: Gemcitabine	Hoffmann-La Roche	Phase 2	---
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-cell Lymphoma	Drug: Obinutuzumab Drug: Glofitamab Drug: Rituximab Drug: Tocilizumab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3	---